FDA Adverse Event Malfunction Summary report: N

ARCHITECT IPTH

MDR report key: 3260087 · Received August 1, 2013

Report

Report Number
3002809144-2013-00152
Event Type
Malfunction
Date Received
August 1, 2013
Date of Event
July 8, 2013
Report Date
July 9, 2013
Manufacturer
ABBOTT GERMANY
Product Code
CEW
PMA / PMN Number
K063232
Removal / Correction Number
3002809144-02/13/14-001R
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
TU
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THIS REPORT IS BEING FILED ON AN INTERNATIONAL PRODUCT, LIST NUMBER 08K25-20, THAT HAS A SIMILAR PRODUCT DISTRIBUTED IN THE US, LIST NUMBER 08K25-27. (B)(4). AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.

Additional Manufacturer Narrative · 1

ABBOTT HAS CONFIRMED THAT A PERFORMANCE SHIFT IN THE ARCHITECT INTACT PTH ASSAY HAS THE POTENTIAL TO GENERATE FALSELY ELEVATED RESULTS ON PATIENT SAMPLES. A PRODUCT RECALL HAS BEEN ISSUED AND AN INVESTIGATION IS ONGOING TO IDENTIFY THE CAUSE OF THE ISSUE. A FOLLOW UP REPORT WILL BE SUBMITTED WHEN THE INVESTIGATION IS COMPLETE.

Additional Manufacturer Narrative · 1

ACCURACY TESTING WAS COMPLETED TO EVALUATE THE ASSAY PERFORMANCE USING A FILE KIT OF REAGENT LOT 01512K000. THE TESTING PASSED. A STUDY WAS REVIEWED "PERFORMANCE CHARACTERISTICS OF SIX INTACT PARATHYROID HORMONE ASSAYS". SONIA L. LA'ULU, AND WILLIAM L. ROBERTS, MD, PHD. AM J CLIN PATHOL 2010;134:930-938, 2010. THIS STUDY LOOKED AT THE PERFORMANCE CHARACTERISTICS OF 6 INTACT PARATHYROID HORMONE ASSAYS, INCLUDING THE ARCHITECT WHICH WAS THE COMPARISON METHOD. FOR METHOD COMPARISON, SERUM AND EDTA PLASMA SAMPLES WERE TESTED BY ALL METHODS. OVERALL THE STUDY FOUND GOOD CORRELATION FOR ALL METHODS, BUT DID INDICATE THERE WAS SIGNIFICANT BIAS BETWEEN METHODS. THE STUDY ALSO CONCLUDED THAT THERE ARE MANY FACTORS THAT POTENTIALLY INFLUENCE VARIABILITY FOR PTH MEASUREMENTS, INCLUDING THE METHOD USED, PTH SOURCE (SYNTHETIC VS ENDOGENOUS), POPULATION EVALUATED, VITAMIN D STATUS, PREANALYTIC VARIABLES SUCH AS SAMPLE MATRIX, AND STORAGE TIME AND TEMPERATURE. THE STUDY ASSESSED SOME OF THESE FACTORS THAT CAN PRODUCE VARIABILITY AND CONFIRMED THAT THERE IS VARIABILITY BETWEEN PTH ASSAYS. IN CONCLUSION THE STUDY INDICATED THAT STANDARDIZATION EFFORTS ARE WARRANTED AND ASSAY-SPECIFIC DECISION LIMITS ARE REQUIRED. A PRODUCT DEFICIENCY WAS NOT IDENTIFIED FOR THIS ISSUE. IN ADDITION, THERE IS NOT ENOUGH INFORMATION TO REASONABLY SUGGEST A MALFUNCTION HAD OCCURRED.

Additional Manufacturer Narrative · 1

ABBOTT HAS IDENTIFIED INSTABILITY OF THE ARCHITECT INTACT PTH CALIBRATORS TO BE A MAJOR CONTRIBUTOR TO THE OBSERVED INCREASE IN PATIENT SAMPLE VALUES. REDUCED EXPIRATION DATING HAS BEEN IMPLEMENTED TO ADDRESS THE ISSUE. ARCHITECT INTACT PTH CONTROLS ARE MANUFACTURED FROM THE SAME MATRIX MATERIAL AS THE CALIBRATORS. THEREFORE, BOTH ARCHITECT INTACT PTH CALIBRATORS AND CONTROLS WILL HAVE A REDUCED EXPIRATION DATING.

Description of Event or Problem · 1

THE CUSTOMER STATED THAT FALSELY ELEVATED ARCHITECT INTACT PTH RESULTS WERE GENERATED FOR SEVEN PATIENTS. THE CUSTOMER CONSIDERS THE RESULTS TO BE FALSELY ELEVATED BECAUSE THE SAMPLES TESTED LOWER AT ANOTHER LABORATORY USING THE ROCHE COBAS METHOD. THE CUSTOMER STATED THAT ROCHE VALUES WERE HALF THE ARCHITECT VALUES AND THAT THE ROCHE VALUES MATCHED THE CLINICAL HISTORY OF THE PATIENTS. THIS EMDR IS FOR PATIENT 4 OF 7 ((B)(6)). ARCHITECT VALUES WERE 69.8 AND 53.9 PG/ML. ROCHE COBAS VALUE WAS HALF (EXACT VALUE NOT PROVIDED). NO ADVERSE IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
360974 ARCHITECT IPTH INTACT PARATHYROID HORMONE CEW ABBOTT GERMANY 01512K000

Patients

Seq Age Sex Outcome Treatment
1 LIST 03M74-02, SERIAL (B)(4)| ARCHITECT I2000SR ANALYZER| LN 03M74-02 SN (B)(4)| ARCHITECT I2000 ANALYZER| LN 03M74-02 SN (B)(4)| ARCHITECT I2000SR ANALYZER| ARCHITECT I2000SR ANALYZER| LIST 03M74-02, SERIAL (B)(4)